A Hierarchical QSAR Model for Urinary Excretion of Drugs in Humans as a Predictive Tool for Biotransformation
暂无分享,去创建一个
Mark T. D. Cronin | Judith C. Duffy | M. Cronin | P. Rowe | J. Duffy | Philip H. Rowe | N. Manga | Na'ngono Manga
[1] S. Ekins,et al. Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.
[2] John G. Topliss,et al. QSAR Model for Drug Human Oral Bioavailability1 , 2000 .
[3] Lawrence X. Yu,et al. Predicting Human Oral Bioavailability of a Compound: Development of a Novel Quantitative Structure-Bioavailability Relationship , 2000, Pharmaceutical Research.
[4] Hiren Patel,et al. A Novel Index for the Description of Molecular Linearity , 2001, J. Chem. Inf. Comput. Sci..
[5] Han van de Waterbeemd,et al. Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..
[6] J. D. Elliott,et al. Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.
[7] J. Dearden,et al. Partitioning and lipophilicity in quantitative structure-activity relationships. , 1985, Environmental health perspectives.
[8] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[9] R. Rahmani,et al. Relationships betweenin vitro andin vivo biotransformation of drugs in humans and animals: pharmaco-toxicological consequences , 1995, Cell Biology and Toxicology.
[10] Pravin Chaturvedi,et al. Design principles for orally bioavailable drugs , 1996 .
[11] T. Kennedy. Managing the drug discovery/development interface , 1997 .
[12] Rodrigues Ad,et al. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. , 1997 .